6m from the USD10m milestone payment received from Kyowa Hakko and the USD3m from the Daiichi Sankyo AKIP
agreement, partially offset by an increase of USD0.
ARQ 092 is the first compound to emerge from the parties' November 2008 contract to partner on research utilising the AKIP
(ArQule Kinase Inhibitor Platform) technology to generate novel, selective and potent small molecule kinase inhibitors.
Consistent with the existing AKIP
collaboration, the economic terms provided for in the expanded agreement include payments for research support, licensing fees for compounds discovered as a result of this research, milestone payments related to clinical development, regulatory review and sales, and tiered royalty payments on net sales of each product.